PL2201100T3 - Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu - Google Patents
Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniuInfo
- Publication number
- PL2201100T3 PL2201100T3 PL08804137.1T PL08804137T PL2201100T3 PL 2201100 T3 PL2201100 T3 PL 2201100T3 PL 08804137 T PL08804137 T PL 08804137T PL 2201100 T3 PL2201100 T3 PL 2201100T3
- Authority
- PL
- Poland
- Prior art keywords
- cells
- vaccination
- enhancing
- antigen presenting
- human antigen
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 210000000612 antigen-presenting cell Anatomy 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000004936 stimulating effect Effects 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4272—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4273—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2007059732 | 2007-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2201100T3 true PL2201100T3 (pl) | 2016-10-31 |
Family
ID=38969592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08804137.1T PL2201100T3 (pl) | 2007-09-14 | 2008-09-12 | Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8476419B2 (pl) |
| DK (1) | DK2201100T3 (pl) |
| ES (1) | ES2573458T3 (pl) |
| HU (1) | HUE029164T2 (pl) |
| PL (1) | PL2201100T3 (pl) |
| PT (1) | PT2201100E (pl) |
| WO (1) | WO2009034172A1 (pl) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130108663A1 (en) * | 2007-09-14 | 2013-05-02 | Vrije Universiteit Brussel | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
| US9408909B2 (en) | 2007-09-14 | 2016-08-09 | Vrije Universiteit Brussel | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010102278A1 (en) * | 2009-03-06 | 2010-09-10 | President And Fellows Of Harvard College | Methods and compositions for the generation and maintenance of regulatory t cells |
| US9211321B2 (en) | 2009-10-27 | 2015-12-15 | Immunicum Ab | Method for proliferation of antigen-specific T cells |
| RU2447899C2 (ru) * | 2010-05-27 | 2012-04-20 | Михаил Валентинович Филатов | Композиция для лечения гепатита с и способ лечения гепатита с |
| US9492529B2 (en) | 2011-04-13 | 2016-11-15 | Immunicum Ab | Method for priming of T cells |
| WO2013083254A1 (en) | 2011-12-09 | 2013-06-13 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| WO2014070663A1 (en) * | 2012-10-29 | 2014-05-08 | Anderson David E | Compositions and methods for diagnosis and treatment of malignant gliomas |
| CN104177499B (zh) * | 2013-05-27 | 2019-01-08 | 上海雅科生物科技有限公司 | 一种嵌合抗原受体、编码基因、表达载体及其应用 |
| RS64268B1 (sr) | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| WO2015071295A1 (en) | 2013-11-12 | 2015-05-21 | Vrije Universiteit Brussel | Rna transcription vector and uses thereof |
| WO2015079439A1 (en) | 2013-11-26 | 2015-06-04 | Technion Research And Development Foundation Limited | Neuronal modulation |
| MA50819A (fr) | 2014-12-23 | 2021-04-07 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
| GB201501017D0 (en) * | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| SMT201900702T1 (it) | 2015-01-08 | 2020-01-14 | Genmab As | Agenti agonistici leganti il recettore del tnf |
| IL272798B2 (en) * | 2015-01-08 | 2024-05-01 | BioNTech SE | Agonistic tnf receptor binding agents |
| AU2016251687C1 (en) * | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| CN108463547A (zh) * | 2015-10-28 | 2018-08-28 | 生命技术股份公司 | 通过改变细胞表面信号和信号比选择性扩增不同的t细胞亚群 |
| KR101829978B1 (ko) * | 2016-03-30 | 2018-02-20 | 가톨릭대학교 산학협력단 | B 세포 백신 및 이의 용도 |
| CA3024509A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| PL3458083T3 (pl) | 2016-05-18 | 2023-03-13 | Modernatx, Inc. | Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania |
| CA3042015A1 (en) * | 2016-10-26 | 2018-05-03 | Modernatx, Inc. | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
| US11422127B2 (en) * | 2016-12-07 | 2022-08-23 | Albany Medical College | Ex vivo antigen and adjuvant pulsed peripheral blood mononuclear cells as a screening platform for candidate novel vaccines and candidate antigens |
| MX2019009070A (es) | 2017-02-01 | 2019-10-30 | Modernatx Inc | Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion. |
| KR20240144261A (ko) | 2017-02-28 | 2024-10-02 | 사노피 | 치료적 rna |
| AU2018270111B2 (en) | 2017-05-18 | 2022-07-14 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| JP7301002B2 (ja) | 2017-05-30 | 2023-06-30 | ブリストル-マイヤーズ スクイブ カンパニー | 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物 |
| WO2018222718A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
| KR20250020679A (ko) | 2017-08-04 | 2025-02-11 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
| CA3104833A1 (en) | 2018-07-16 | 2020-01-23 | Dcprime B.V. | A combination product for use in tumor vaccination. |
| CN113165866A (zh) * | 2018-10-04 | 2021-07-23 | Sqz生物技术公司 | 细胞内递送生物分子以增强抗原呈递细胞功能 |
| JP7496623B2 (ja) * | 2019-01-04 | 2024-06-07 | イーザアールエヌーエー イムノセラピーズ エンヴェー | mRNAワクチン |
| US11052144B2 (en) | 2019-04-25 | 2021-07-06 | Dcprime B.V. | Methods of tumor vaccination |
| US20220362360A1 (en) * | 2019-04-26 | 2022-11-17 | Etherna Immunotherapies Nv | Mrna formulation |
| CN110151999A (zh) * | 2019-05-22 | 2019-08-23 | 中国人民解放军第四军医大学 | 用于抑制恶性黑色素瘤进展的靶向药物 |
| AU2021236879A1 (en) * | 2020-03-16 | 2022-11-10 | Vrije Universiteit Brussel | A mixture of mRNA to enhance the potency of dendritic cells |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| WO2022003568A1 (en) | 2020-06-30 | 2022-01-06 | Dcprime B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
| KR20230135075A (ko) | 2021-01-22 | 2023-09-22 | 멘두스 비.브이. | 종양 백신접종 방법 |
| CN114317435B (zh) * | 2021-12-30 | 2024-02-27 | 杭州芯递力生物科技有限公司 | 一种获得抗原特异性t细胞的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6734014B1 (en) * | 1996-02-08 | 2004-05-11 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for transforming dendritic cells and activating T cells |
| US6969609B1 (en) * | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| EP1651755B1 (en) * | 2003-08-04 | 2010-10-13 | IMBA-Institut für Molekulare Biotechnologie GmbH | Method for immunotherapy of tumors |
| AU2005250408B2 (en) * | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| DE602005025005D1 (de) * | 2004-10-07 | 2011-01-05 | Argos Therapeutics Inc | Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung |
| EP1806395A1 (en) | 2006-01-06 | 2007-07-11 | Stichting Sanquin Bloedvoorziening | Maturation of dendritic cells |
-
2008
- 2008-09-12 PT PT08804137T patent/PT2201100E/pt unknown
- 2008-09-12 WO PCT/EP2008/062174 patent/WO2009034172A1/en not_active Ceased
- 2008-09-12 ES ES08804137.1T patent/ES2573458T3/es active Active
- 2008-09-12 US US12/677,476 patent/US8476419B2/en active Active
- 2008-09-12 DK DK08804137.1T patent/DK2201100T3/en active
- 2008-09-12 HU HUE08804137A patent/HUE029164T2/hu unknown
- 2008-09-12 PL PL08804137.1T patent/PL2201100T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE029164T2 (hu) | 2017-02-28 |
| PT2201100E (pt) | 2016-06-03 |
| DK2201100T3 (en) | 2016-05-30 |
| US8476419B2 (en) | 2013-07-02 |
| US20100215674A1 (en) | 2010-08-26 |
| ES2573458T3 (es) | 2016-06-08 |
| WO2009034172A1 (en) | 2009-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE029164T2 (hu) | Humán antigén-prezentáló sejtek T-sejteket stimuláló képességének fokozása és azok alkalmazása vakcinázásra | |
| IL223376A0 (en) | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies | |
| PL2700708T3 (pl) | Zwiększanie zdolności limfocytów T do stymulacji ludzkiego antygenu prezentującego komórki in vitro oraz in vivo i jego zastosowanie w szczepieniu | |
| IL200572A0 (en) | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases | |
| EP2210583A4 (en) | GEL SHEET AND SHEET-LIKE COSMETIC PREPARATION USING THE SAME | |
| GB2465291B (en) | Human pluripotent stem cells and their medical use | |
| LT2282758T (lt) | Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams | |
| PL2476435T3 (pl) | Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych | |
| SI2633077T1 (sl) | Analitski postopki in mreže za uporabo pri identifikaciji sredstev, ki inducirajo senzibilizacijo v človeški koži | |
| ZA200905408B (en) | Human cytomegalovirus neutralising antibodies and use thereof | |
| ZA201102004B (en) | Antibodies against human il 17 and uses thereof | |
| PT2291394T (pt) | Proteínas de fusão e seus usos no diagnóstico e tratamento de leishmaniose | |
| ZA201109453B (en) | Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease | |
| IL205780A0 (en) | Fviii peptides and their use in tolerising haemophiliacs | |
| GB0605702D0 (en) | Materials and methods for immune cell stimulation | |
| IL208579A0 (en) | Methods and use of inducing a poptosis in cancer cells | |
| IL217209A0 (en) | Novel antibodies and their uses in therapeutic and diagnostic methods | |
| PT2465523E (pt) | Péptidos derivados de fviii e seu uso na tolerização de hemofílicos | |
| GB0908868D0 (en) | Depsipeptide and their therapeutic use | |
| PL1945673T3 (pl) | Ukierunkowywanie i śledzenie antygenów w żywych komórkach | |
| EP2638167A4 (en) | DOMINANT NEGATIVE MUTANT KIP PROTEINS IN ZEA-MAIZE AND METHOD FOR THEIR USE | |
| EP2115127A4 (en) | METHOD AND COMPOSITIONS FOR IMPROVING CELL HEALTH IN CULTURES | |
| GB0505908D0 (en) | Antibodies and their use in therapy | |
| HK1170538A (en) | Novel antibodies and their uses in therapeutic and diagnostic methods | |
| GB0424871D0 (en) | Antibodies and their use in therapy |